AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Uckun, F. M.
Right arrow Articles by Myers, D. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Uckun, F. M.
Right arrow Articles by Myers, D. E.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 1998, p. 383-388, Vol. 42, No. 2
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

TXU (Anti-CD7)-Pokeweed Antiviral Protein as a Potent Inhibitor of Human Immunodeficiency Virus

Fatih M. Uckun,1,2,* Lisa M. Chelstrom,2 Lisa Tuel-Ahlgren,2 Ilker Dibirdik,2 James D. Irvin,3 Mridula-Chandan Langlie,4 and Dorothea E. Myers4

Wayne Hughes Institute, St. Paul, Minnesota1; Biotherapy Program, University of Minnesota, Minneapolis, Minnesota2; Department of Chemistry, Southwest Texas State University, San Marcos, Texas3; and Alexander Parker Pharmaceuticals, Inc., Roseville, Minnesota4

Received 13 August 1997/Returned for modification 3 November 1997/Accepted 25 November 1997

We have evaluated the clinical potential of TXU (anti-CD7)-pokeweed antiviral protein (PAP) immunoconjugate (TXU-PAP) as a new biotherapeutic anti-human immunodeficiency virus (anti-HIV) agent by evaluating its anti-HIV type 1 (anti-HIV-1) activity in vitro, as well as in a surrogate human peripheral blood lymphocyte-severe combined immunodeficient (Hu-PBL-SCID) mouse model of human AIDS. The present report documents in a side-by-side comparison the superior in vitro anti-HIV-1 activity of TXU-PAP compared to the activities of zidovudine, 2',3'-didehydro-2',3'-dideoxythymidine, unconjugated PAP, and B53-PAP, an anti-CD4-PAP immunoconjugate. Notably, TXU-PAP elicited potent anti-HIV activity in the Hu-PBL-SCID mouse model of human AIDS without any side effects and at doses that were very well tolerated by cynomolgus monkeys. Furthermore, plasma samples from TXU-PAP-treated cynomolgus monkeys showed potent anti-HIV-1 activity in vitro.

* Corresponding author. Mailing address: Wayne Hughes Institute, 2665 Long Lake Rd., St. Paul, MN 55113. Phone: (612) 697-9228. Fax: (612) 697-1042. E-mail: fatih_uckun{at}mercury.ih.org.

Antimicrobial Agents and Chemotherapy, February 1998, p. 383-388, Vol. 42, No. 2
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 1998 by the American Society for Microbiology. All rights reserved.